-
1
-
-
37049183697
-
Human Breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG. Human Breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 1987;235:177-182.
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
-
2
-
-
0036467826
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
-
DOI 10.1200/JCO.20.3.719
-
Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726. (Pubitemid 34111379)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.3
, pp. 719-726
-
-
Vogel, C.L.1
Cobleigh, M.A.2
Tripathy, D.3
Gutheil, J.C.4
Harris, L.N.5
Fehrenbacher, L.6
Slamon, D.J.7
Murphy, M.8
Novotny, W.F.9
Burchmore, M.10
Shak, S.11
Stewart, S.J.12
Press, M.13
-
3
-
-
0032850677
-
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
-
Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648. (Pubitemid 29415219)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.9
, pp. 2639-2648
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
Robert, N.J.4
Scholl, S.5
Fehrenbacher, L.6
Wolter, J.M.7
Paton, V.8
Shak, S.9
Lieberman, G.10
Slamon, D.J.11
-
4
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2
-
DOI 10.1056/NEJM200103153441101
-
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med. 2001;244:783-792. (Pubitemid 32222155)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.11
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
Fleming, T.7
Eiermann, W.8
Wolter, J.9
Pegram, M.10
Baselga, J.11
Norton, L.12
-
5
-
-
32244435101
-
Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: Results of a randomized phase II trial by the M77001 study group
-
Marty M, Cognetti F, Maraninchi D, et al. Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: results of a randomized phase II trial by the M77001 study group. J Clin Oncol. 2005;23:4247-4250.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4247-4250
-
-
Marty, M.1
Cognetti, F.2
Maraninchi, D.3
-
6
-
-
33845914783
-
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial
-
DOI 10.1016/S0140-6736(07)60028-2, PII S0140673607600282
-
Smith I, Procter M, Gelber RD, et al. Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29-36. (Pubitemid 46039831)
-
(2007)
Lancet
, vol.369
, Issue.9555
, pp. 29-36
-
-
Smith, I.1
Procter, M.2
Gelber, R.D.3
Guillaume, S.4
Feyereislova, A.5
Dowsett, M.6
Goldhirsch, A.7
Untch, M.8
Mariani, G.9
Baselga, J.10
Kaufmann, M.11
Cameron, D.12
Bell, R.13
Bergh, J.14
Coleman, R.15
Wardley, A.16
Harbeck, N.17
Lopez, R.I.18
Mallmann, P.19
Gelmon, K.20
Wilcken, N.21
Wist, E.22
Sanchez Rovira, P.23
Piccart-Gebhart, M.J.24
more..
-
7
-
-
69349095288
-
Adjuvant Trastuzumab treatment
-
French National Cancer Institute - French agency for sanitary security of health products.
-
French National Cancer Institute - French agency for sanitary security of health products. Adjuvant Trastuzumab treatment. Protocole temporaire de traitement en situation adjuvante. 2005.
-
(2005)
Protocole Temporaire de Traitement en Situation Adjuvante
-
-
-
9
-
-
33846651627
-
Use of the Monoclonal Antibody Anti-human Epidermal Growth Factor Receptor 2 (Anti-HER2), Trastuzumab, in the Treatment of Metastatic Breast Cancer: A Cost-effectiveness Analysis
-
DOI 10.1016/j.clon.2006.11.004, PII S0936655506004183
-
Poncet B, Bachelot T, Colin C, et al. Use of the monoclonal antibody anti-human epidermal growth factor receptor 2 (anti-HER2), trastuzumab, in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Clin Oncol. 2007;19:162-163. (Pubitemid 46187487)
-
(2007)
Clinical Oncology
, vol.19
, Issue.2
, pp. 162-163
-
-
Poncet, B.1
Bachelot, T.2
Colin, C.3
Orfeuvre, H.4
Ganne, C.5
Peaud, P.Y.6
Jacquin, J.P.7
Salles, B.8
Tigaud, J.D.9
Mechin-Cretinon, I.10
Marechal, F.11
Trillet-Lenoir, V.12
-
10
-
-
55449105261
-
Use of the monoclonal antibody anti-human epidermal growth factor receptor 2 (anti-HER2), trastuzumab, in the treatment of metastatic breast cancer: A cost-effectiveness analysis
-
Poncet B, Bachelot T, Colin C, et al. Use of the monoclonal antibody anti-human epidermal growth factor receptor 2 (anti-HER2), trastuzumab, in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Am J Clin Oncol. 2008;4:363-368.
-
(2008)
Am J Clin Oncol
, vol.4
, pp. 363-368
-
-
Poncet, B.1
Bachelot, T.2
Colin, C.3
-
11
-
-
0041885349
-
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm
-
Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003;21:2889-2895.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2889-2895
-
-
Burstein, H.J.1
Harris, L.N.2
Marcom, P.K.3
-
12
-
-
33749344930
-
Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: An international phase II trial
-
DOI 10.1038/sj.bjc.6603351, PII 6603351
-
Chan A, Martin M, Untch M, et al. Navelbine Herceptin Project. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer. 2006;95:788-793. (Pubitemid 44498091)
-
(2006)
British Journal of Cancer
, vol.95
, Issue.7
, pp. 788-793
-
-
Chan, A.1
Martin, M.2
Untch, M.3
Gil, M.G.4
Guillem-Porta, V.5
Wojtukiewicz, M.6
Kellokumpu-Lehtinen, P.7
Sommer, H.L.8
Georgoulias, V.9
Battelli, N.10
Pawlicki, M.11
Aubert, D.12
Bourlard, T.13
Gasmi, J.14
Villanova, G.15
Petruzelka, L.16
-
13
-
-
34548178720
-
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
-
DOI 10.1002/cncr.22885
-
Burstein HJ, Keshavia A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007;110:965-972. (Pubitemid 47312860)
-
(2007)
Cancer
, vol.110
, Issue.5
, pp. 965-972
-
-
Burstein, H.J.1
Keshaviah, A.2
Baron, A.D.3
Hart, R.D.4
Lambert-Falls, R.5
Marcom, P.K.6
Gelman, R.7
Winer, E.P.8
-
14
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
Therasse P, Arbuck SG, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
-
(2000)
Journal of the National Cancer Institute
, vol.92
, Issue.3
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
Van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
16
-
-
33846568336
-
American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
-
Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18.
-
(2007)
Arch Pathol Lab Med
, vol.131
, pp. 18
-
-
Wolff, A.C.1
Hammond, M.E.2
Schwartz, J.N.3
|